Bone Biologics (NASDAQ:BBLG) Trading Down 0.5% – Time to Sell?

Shares of Bone Biologics Corp. (NASDAQ:BBLG) were down 0.5% on Wednesday . The company traded as low as $1.9246 and last traded at $2.10. Approximately 43,801 shares changed hands during trading, an increase of 8% from the average daily volume of 40,407 shares. The stock had previously closed at $2.11.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BBLG. Wall Street Zen upgraded Bone Biologics from a “sell” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Bone Biologics currently has a consensus rating of “Sell”.

Bone Biologics Stock Down 0.5%

The company has a market capitalization of $3.78 million, a price-to-earnings ratio of -0.58 and a beta of 0.75. The business has a fifty day simple moving average of $2.02 and a two-hundred day simple moving average of $2.81.

Bone Biologics (NASDAQ:BBLG) last posted its earnings results on Friday, November 14th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.86. As a group, equities analysts predict that Bone Biologics Corp. will post -5 earnings per share for the current fiscal year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.